Sitagliptin could trigger pancreatitis

A drug widely used to treat Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater risk of pancreas cancer in long-term users, UCLA scientists have found. As per a research findings reported in the online edition of the journal Diabetes, scientists from the Larry L. Hillblom Islet Research Center at UCLA observed that sitagliptin, sold in pill form as Januvia, caused abnormalities in the pancreas that are recognized as risk factors for pancreatitis and, with time, pancreas cancer in humans. Januvia is marketed by Merck and Co. Inc. Sitagliptin is a member of a new class of drugs that enhance the actions of the gut hormone known as glucagon-like peptide 1 (GLP-1), which has been shown to be effective in lowering blood sugar in people with Type 2 diabetes. The study is available at http://diabetes.diabetesjournals.org/cgi/content/abstract/db09-0058v1……..

Reducing sugar and increasing fiber intake

Reducing sugar intake by the equivalent of one can of soda per day and increasing fiber intake by the amount equivalent to one half cup of beans per day appears to improve risk factors linked to type 2 diabetes in Latino adolescents, as per a report in the recent issue of Archives of Pediatrics and Adolescent Medicine, one of the JAMA/Archives journals……..

Diabetes transmitted from parents to children

A new study in the recent issue of the Journal of Lipid Research suggests an unusual form of inheritance may have a role in the rising rate of diabetes, particularly in children and young adults, in the United States. DNA is the primary mechanism of inheritance; kids get half their genes from mom and half from dad. However, researchers are just starting to understand additional kinds of inheritance like metabolic programming, which occurs when an insult during a critical period of development, either in the womb or soon after birth, triggers permanent changes in metabolism……..

Battling Diabetes with Beta Cells

Affecting eight percent of America’s population, diabetes can lead to blindness, kidney failure, strokes and heart disease. Thanks to Tel Aviv University researchers, a new cure — based on advances in cell treatment — may be within reach. Prof. Shimon Efrat from TAU’s Sackler Faculty of Medicine, whose research group is among world leaders in beta cell expansion, has developed a way to cultivate cells derived from insulin-producing beta cells from human tissue in the laboratory. It may be possible to implant these new healthy cells into patients with type 1 diabetes……..